Tesofensine

also known as: NS2330, Triple monoamine reuptake inhibitor

Weight LossCognitiveadvancedOral

Half-life: ~17 days (accumulates with daily dosing)

About

Tesofensine is a triple monoamine reuptake inhibitor (norepinephrine, dopamine, serotonin) originally developed for Alzheimer's and Parkinson's disease. Phase 2 obesity trials showed remarkable weight loss of 10–14% over 24 weeks — surpassing any approved agent at the time. It is not a peptide per se but is commonly included in peptide clinic protocols.

Mechanism of Action

Inhibits reuptake of norepinephrine (appetite suppression, energy expenditure), dopamine (reward, motivation, satiety), and serotonin (mood, satiety), producing powerful appetite suppression and increased basal metabolic rate.

Primary Benefits

Powerful appetite suppression
Significant weight loss (10–14%)
Increased energy and motivation
Improved mood
Cognitive enhancement (dopaminergic)

Side Effects & Considerations

Elevated heart rate and blood pressure (monitor carefully)
Dry mouth
Insomnia
Constipation
Headache
Potential for dependence/abuse at high doses
Not appropriate for cardiovascular disease patients

Stacking Guide

Synergistic Stacks

Tirzepatide

GLP-1 agonist + Tesofensine combines gut-hormone appetite suppression with CNS appetite suppression — very effective but requires careful monitoring.

Redundant / Avoid Together

None listed.

Complementary Cycles

AOD9604

Tesofensine suppresses appetite via CNS; AOD9604 mobilizes fat via β3-adrenergic pathway — add during Tesofensine cycles.

Storage & Reconstitution

Storage

Store at room temperature.

Goals Addressed

Weight Loss

Quick Stats

Half-Life: ~17 days (accumulates with daily dosing)
Admin Routes: Oral
Experience Level: advanced

Back to Library Add to Cycle Builder